190 related articles for article (PubMed ID: 27440271)
21. Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia.
Badar T; Handisides DR; Benito JM; Richie MA; Borthakur G; Jabbour E; Harutyunyan K; Konoplev S; Faderl S; Kroll S; Andreeff M; Pearce T; Kantarjian HM; Cortes JE; Thomas DA; Konopleva M
Am J Hematol; 2016 Aug; 91(8):800-5. PubMed ID: 27169385
[TBL] [Abstract][Full Text] [Related]
22. Intraprocedural 3D Quantification of Lipiodol Deposition on Cone-Beam CT Predicts Tumor Response After Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma.
Wang Z; Chen R; Duran R; Zhao Y; Yenokyan G; Chapiro J; Schernthaner R; Radaelli A; Lin M; Geschwind JF
Cardiovasc Intervent Radiol; 2015 Dec; 38(6):1548-56. PubMed ID: 26001366
[TBL] [Abstract][Full Text] [Related]
23. Hypoxic targeting and activating TH-302 loaded transcatheter arterial embolization microsphere.
Ma P; Chen J; Qu H; Li Y; Li X; Tang X; Song Z; Xin H; Zhang J; Nai J; Li Z; Wang Z
Drug Deliv; 2020 Dec; 27(1):1412-1424. PubMed ID: 33096947
[TBL] [Abstract][Full Text] [Related]
24. Heated lipiodol as an embolization agent for transhepatic arterial embolization in VX2 rabbit liver cancer model.
Cao W; Wan Y; Liang ZH; Duan YY; Liu X; Wang ZM; Liu YY; Zhu J; Liu XT; Zhang HX
Eur J Radiol; 2010 Feb; 73(2):412-9. PubMed ID: 19091502
[TBL] [Abstract][Full Text] [Related]
25. [Effects of transcatheter arterial chemoembolization with pingyangmycin-lipiodol emulsion on VX2 liver tumors in rabbits].
Liu X; Luo XP; Cao WT; Deng H
Zhonghua Gan Zang Bing Za Zhi; 2012 Aug; 20(8):611-6. PubMed ID: 23207156
[TBL] [Abstract][Full Text] [Related]
26. Use of Ethanol in the Trans-Arterial Lipiodol Embolization (TAELE) of Intermediated-Stage HCC: Is This Safer than Conventional Trans-Arterial Chemo-Embolization (c-TACE)?
Somma F; D'Angelo R; Serra N; Gatta G; Grassi R; Fiore F
PLoS One; 2015; 10(6):e0129573. PubMed ID: 26110810
[TBL] [Abstract][Full Text] [Related]
27. Evofosfamide, a new horizon in the treatment of pancreatic cancer.
Pourmorteza M; Rahman ZU; Young M
Anticancer Drugs; 2016 Sep; 27(8):723-5. PubMed ID: 27232101
[TBL] [Abstract][Full Text] [Related]
28. The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy.
Nytko KJ; Grgic I; Bender S; Ott J; Guckenberger M; Riesterer O; Pruschy M
Oncotarget; 2017 Apr; 8(14):23702-23712. PubMed ID: 28423594
[TBL] [Abstract][Full Text] [Related]
29. Predicting early necrosis of colorectal liver metastases using volumetric enhancement on baseline MRI and oil deposition on post-cTACE unenhanced CT.
Hazhirkarzar B; Tang H; Ghadimi M; Baghdadi A; Motaghi M; Wu Q; Shaghaghi M; Kamel I
Abdom Radiol (NY); 2021 Oct; 46(10):4610-4618. PubMed ID: 34089068
[TBL] [Abstract][Full Text] [Related]
30. Stabilization Improves Theranostic Properties of Lipiodol
Deschamps F; Farouil G; Gonzalez W; Robic C; Paci A; Mir LM; Tselikas L; de Baère T
Cardiovasc Intervent Radiol; 2017 Jun; 40(6):907-913. PubMed ID: 28271329
[TBL] [Abstract][Full Text] [Related]
31. Targeting Hypoxia Using Evofosfamide and Companion Hypoxia Imaging of FMISO-PET in Advanced Biliary Tract Cancer.
Yoon J; Kang SY; Lee KH; Cheon GJ; Oh DY
Cancer Res Treat; 2021 Apr; 53(2):471-479. PubMed ID: 33091966
[TBL] [Abstract][Full Text] [Related]
32. Deep-learning and MR images to target hypoxic habitats with evofosfamide in preclinical models of sarcoma.
Jardim-Perassi BV; Mu W; Huang S; Tomaszewski MR; Poleszczuk J; Abdalah MA; Budzevich MM; Dominguez-Viqueira W; Reed DR; Bui MM; Johnson JO; Martinez GV; Gillies RJ
Theranostics; 2021; 11(11):5313-5329. PubMed ID: 33859749
[No Abstract] [Full Text] [Related]
33. Intra-arterial interleukin-12 gene delivery combined with chemoembolization: anti-tumor effect in a rabbit hepatocellular carcinoma (HCC) model.
Xia X; Li X; Feng G; Zheng C; Liang H; Zhou G
Acta Radiol; 2013 Jul; 54(6):684-9. PubMed ID: 23507934
[TBL] [Abstract][Full Text] [Related]
34. Intra-arterially infused carbon dioxide-saturated solution for sensitizing the anticancer effect of cisplatin in a rabbit VX2 liver tumor model.
Katayama N; Sugimoto K; Okada T; Ueha T; Sakai Y; Akiyoshi H; Mie K; Ueshima E; Sofue K; Koide Y; Tani R; Gentsu T; Yamaguchi M
Int J Oncol; 2017 Aug; 51(2):695-701. PubMed ID: 28656217
[TBL] [Abstract][Full Text] [Related]
35. Transarterial Chemoembolization Using Sorafenib in a Rabbit VX2 Liver Tumor Model: Pharmacokinetics and Antitumor Effect.
Kim GM; Kim MD; Kim do Y; Kim SH; Won JY; Park SI; Lee do Y; Shin W; Shin M
J Vasc Interv Radiol; 2016 Jul; 27(7):1086-92. PubMed ID: 27179404
[TBL] [Abstract][Full Text] [Related]
36. Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial.
Grande E; Rodriguez-Antona C; López C; Alonso-Gordoa T; Benavent M; Capdevila J; Teulé A; Custodio A; Sevilla I; Hernando J; Gajate P; Molina-Cerrillo J; Díez JJ; Santos M; Lanillos J; García-Carbonero R
Oncologist; 2021 Nov; 26(11):941-949. PubMed ID: 34190375
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic effects of transarterial infusion of lipiodol and ethanol in various ratios in a rabbit VX2 tumor model.
Gao F; Qian T; Chen MZ; Yin HB; Xu YL
Diagn Interv Radiol; 2015; 21(3):241-6. PubMed ID: 25858527
[TBL] [Abstract][Full Text] [Related]
38. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer.
Sun JD; Liu Q; Wang J; Ahluwalia D; Ferraro D; Wang Y; Duan JX; Ammons WS; Curd JG; Matteucci MD; Hart CP
Clin Cancer Res; 2012 Feb; 18(3):758-70. PubMed ID: 22184053
[TBL] [Abstract][Full Text] [Related]
39. Antitumor properties of arsenic trioxide-loaded CalliSpheres
Duan X; Li H; Han X; Ren J; Li F; Ju S; Wang M; Wang W
Am J Transl Res; 2020; 12(9):5511-5524. PubMed ID: 33042434
[TBL] [Abstract][Full Text] [Related]
40. Functional CRISPR and shRNA Screens Identify Involvement of Mitochondrial Electron Transport in the Activation of Evofosfamide.
Hunter FW; Devaux JBL; Meng F; Hong CR; Khan A; Tsai P; Ketela TW; Sharma I; Kakadia PM; Marastoni S; Shalev Z; Hickey AJR; Print CG; Bohlander SK; Hart CP; Wouters BG; Wilson WR
Mol Pharmacol; 2019 Jun; 95(6):638-651. PubMed ID: 30979813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
